arwr-20240221

0001628280-24-005998.txt : 20240222 0001628280-24-005998.hdr.sgml : 20240222 20240221174218 ACCESSION NUMBER: 0001628280-24-005998 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240221 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000879407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460408024 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38042 FILM NUMBER: 24661296 BUSINESS ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: SUITE 700 CITY: PASADENA STATE: CA ZIP: 91105 BUSINESS PHONE: 626-696-4702 MAIL ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: SUITE 700 CITY: PASADENA STATE: CA ZIP: 91105 FORMER COMPANY: FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP DATE OF NAME CHANGE: 20040112 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE GROUP INC DATE OF NAME CHANGE: 20020509 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE INC DATE OF NAME CHANGE: 19940224 8-K 1 arwr-20240221.htm 8-K arwr-20240221

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

February 21, 2024

Date of Report

(Date of earliest event reported)

Arrowhead Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38042

46-0408024

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105

(Address of principal executive offices, including Zip Code)

(626) 304-3400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ARWR

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Hongbo Lu as a Director

On February 21, 2024, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) announced that it would increase the size of the Company's board of directors ("Board") from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024.

Dr. Lu brings over 20 years of healthcare investment experience in both public securities and private companies, including her tenure as a Managing Partner of Vivo Capital, as a Managing Partner at Lilly Asia Ventures (LAV), and as a Managing Director at OrbiMed Advisors. Additionally, Dr. Lu is the founding member of NEXTBio Capital, a newly launched biotech investment firm. Over her investment career, Dr. Lu has previously served on the boards of over 20 healthcare companies, including Turning Point Therapeutics (TPTX), CrownBio (6554.TT), Avedro (AVDR), Terns Pharmaceuticals (TERN), BlossomHill, Zenas, Createrna, Avistone, Echosens, and was extensively involved in the formation of ADARx, Ribox, Visrina, Ablaze, Elpiscience, and Ronovo. Dr. Lu received her undergraduate degree in Material Science and Engineering from Tsinghua University, China, her Ph.D. in Biological Engineering from the University of Washington, and her MBA from the University of California, Berkeley.

Dr. Lu will receive standard compensation and equity awards available to non-employee directors of the Company. The Company’s non-employee director compensation program is described in the “Director Compensation” section of the Company’s definitive Proxy Statement filed with the Securities and Exchange Commission (the “SEC”) on January 26, 2024. In addition, in connection with her appointment, Dr. Lu shall receive a sign-on grant of restricted stock units valued at $761,666. These restricted stock units are scheduled to vest over three years.

There are no family relationships between Dr. Lu and any of the Company’s directors or executive officers, and Dr. Lu does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description

104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 21, 2024


ARROWHEAD PHARMACEUTICALS, INC.

By:						/s/ Kenneth Myszkowski
						Kenneth Myszkowski
						Chief Financial Officer

EX-101.SCH 2 arwr-20240221.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 arwr-20240221_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 4 arwr-20240221_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 21, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 21, 2024
Entity Registrant Name	Arrowhead Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38042
Entity Tax Identification Number	46-0408024
Entity Address, Address Line One	177 E. Colorado Blvd
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Pasadena
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91105
City Area Code	626
Local Phone Number	304-3400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ARWR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0000879407
Amendment Flag	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.arrowheadresearch.com/role/Cover Cover Cover 1 false false All Reports Book All Reports arwr-20240221.htm arwr-20240221.xsd arwr-20240221_lab.xml arwr-20240221_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "arwr-20240221.htm": { "nsprefix": "arwr", "nsuri": "http://www.arrowheadresearch.com/20240221", "dts": { "inline": { "local": [ "arwr-20240221.htm" ] }, "schema": { "local": [ "arwr-20240221.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "arwr-20240221_lab.xml" ] }, "presentationLink": { "local": [ "arwr-20240221_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://www.arrowheadresearch.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "arwr-20240221.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "arwr-20240221.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.arrowheadresearch.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001628280-24-005998-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-005998-xbrl.zip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end XML 15 arwr-20240221_htm.xml IDEA: XBRL DOCUMENT 0000879407 2024-02-21 2024-02-21 0000879407 false 8-K 2024-02-21 Arrowhead Pharmaceuticals, Inc. DE 001-38042 46-0408024 177 E. Colorado Blvd Suite 700 Pasadena CA 91105 626 304-3400 false false false false Common Stock, par value $0.001 per share ARWR NASDAQ false